SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
| العنوان: | SEOM clinical guidelines for pancreatic and biliary tract cancer (2020) |
|---|---|
| المؤلفون: | Andres J. Muñoz Martín, R. Pazo-Cid, Jaime Feliu, R. Vera, A. F. Montes, Rocio Garcia-Carbonero, Juan Maurel, T. M. Mercadé, Alfredo Carrato, Mª A. Gómez-España |
| المساهمون: | Institut Català de la Salut, [Gómez-España MA] Medical Oncology Department, Hospital Universitario Reina Sofía, IMIBIC, CIBERONC, Córdoba, Spain. [Montes AF] Medical Oncology Department, Complexo Hospitalario Universitario de Ourense (CHUO), Orense, Spain. [Garcia-Carbonero R] Medical Oncology Department, Hospital Universitario, UCM, CNIO, CIBERONC, 12 de Octubre, IIS imas12, Madrid, Spain. [Macarulla Mercadé T] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Maurel J] Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain. [Martín AM] Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Zaguán. Repositorio Digital de la Universidad de Zaragoza instname Scientia Clinical & Translational Oncology Zaguán: Repositorio Digital de la Universidad de Zaragoza Universidad de Zaragoza |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Cancer Research, FOLFIRINOX, medicine.medical_treatment, Tracte biliar - Càncer - Tractament - Espanya, Leucovorin, Medical Oncology, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, 030212 general & internal medicine, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias del tracto biliar [ENFERMEDADES], neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias pancreáticas [ENFERMEDADES], Societies, Medical, terapéutica [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Standard treatment, Palliative Care, General Medicine, Chemoradiotherapy, Neoadjuvant Therapy, Oxaliplatin, Geographic Locations::Europe::Spain [GEOGRAPHICALS], Biliary Tract Neoplasms, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Fluorouracil, Adjuvant, medicine.drug, medicine.medical_specialty, Paclitaxel, Clinical Guides in Oncology, Irinotecan, Capecitabine, 03 medical and health sciences, Pancreatic cancer, Internal medicine, Albumins, Chemotherapy, Humans, Neoplasm Staging, Cisplatin, Pàncrees - Càncer - Tractament - Espanya, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms [DISEASES], localizaciones geográficas::Europa (continente)::España [DENOMINACIONES GEOGRÁFICAS], Radiotherapy, business.industry, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Biliary Tract Neoplasms [DISEASES], medicine.disease, Therapeutics [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Gemcitabine, Treatment, Pancreatic Neoplasms, Spain, Concomitant, Quality of Life, Biliary tract cancer, business |
| الوصف: | Chemotherapy; Radiotherapy; Treatment Quimioterapia; Radioterapia; Tratamiento Quimioteràpia; Radioteràpia; Tractament Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. Surgery is the only potentially curative therapy in both cancers, but disease recurrence is frequent. In PC, adjuvant treatment with mFOLFIRINOX has improved overall survival (OS) and in BTC adjuvant treatment with capecitabine seems to improve OS and relapse-free survival. Concomitant radio-chemotherapy could also be considered following R1 surgery in both neoplasms. Neoadjuvant treatment represents the best option for achieving an R0 resection in borderline PC. Upfront systemic chemotherapy is the treatment of choice in unresectable locally advanced PC and BTC; then locoregional therapy could be considered after an initial period of at least 3–4 months of systemic chemotherapy. In metastatic PC, FOLFIRINOX or Gemcitabine plus nab-paclitaxel have improved OS compared with gemcitabine alone. In metastatic BTC, cisplatin plus gemcitabine constitute the standard treatment. Progress in the knowledge of molecular biology has enabled the identification of new targets for therapy with encouraging results that could in the future improve the survival and quality of life of patients with PC and BTC. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af373d2630e13536716a00764b1916fe http://zaguan.unizar.es/record/102205 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....af373d2630e13536716a00764b1916fe |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |